CYBN:CC - InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Four Poster Presentations at the 2023 ACNP Annual Meeting
Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative next-generation psychedelic-based treatment options. The company today announced the presentation of four posters at the American College of Neuropsychopharmacology (“ACNP”) annual meeting taking place in Tampa, Florida, Dec. 3-6, 2023. The presentations include topline data from Cybin’s phase 2 study of CYB003 in major depressive disorder (“MDD”), preclinical data supporting the CYB004 (deuterated ‘DMT’) program, and preclinical data characterizing phenethylamine candidates from the CYB005 program. “We are grateful for the opportunity to share our positive topline phase 2 data readout for CYB003 at one of the leading scientific meetings in neuroscience with world renowned experts in mental health disorders,” said Amir Inamdar, MBBS, DNB (Psych), MFPM, chief medical officer of Cybin. “In our study of CYB003 for MDD, we observed rapid and large improvements in symptoms of depression after single doses, with a clear incremental benefit of a second dose. At the end of the double-blind phase (day 21) for the 12mg dose, CYB003 showed a rapid improvement with a clinically meaningful effect size (2.15) and statistically significant (p=0.0005) difference of 14 points on the Montgomery-Asberg Depression Rating Scale (‘MADRS’) over placebo. Importantly, similar results were obtained in the 16mg group. Response and remission rates were also compelling, exceeding 75%. We are excited to advance this promising drug candidate along the regulatory pathway.”
To view the full press release, visit https://ibn.fm/MSubO
About Cybin Inc.
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Cybin’s goal of revolutionizing mental health care is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN